LY4584180 is an orally bioavailable molecular glue that binds the transcriptional repressor BCL6, inducing BCL6 dimers to form polymers that are marked for ubiquitination and proteasomal degradation. It is being studied in non-Hodgkin lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Small molecule (Molecular glue degrader)
Targets
B-cell lymphoma 6 protein (BCL6)
Mechanism
Degrader of B-cell lymphoma 6 protein (BCL6)
Pathways
E3 ligase ubiquitination, proteasome-mediated degradation, re-expression of BCL6-repressed genes
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.